Unveiling The Oncology Journey: Highlighting Cutting-Edge Capabilities

Cerba Research is redefining oncology clinical trials with a robust suite of services and remarkable expertise in solid and liquid tumor studies. In the past five years, Cerba has conducted nearly 200 oncology trials, contributing to the approval of 24 groundbreaking oncology therapies, including multiple cell and gene therapies. Leveraging advanced diagnostics such as next-generation sequencing (NGS), flow cytometry, and immunohistochemistry, Cerba Research ensures precision in patient profiling and trial outcomes.

Our CE-marked OncoSign assay, encompassing 638 genes, enables comprehensive genomic profiling across diverse cancer types, offering insights into emerging and established biomarkers. With a focus on innovation and speed, Cerba Research guarantees a 15-day turnaround for tumor profiling results. Whether partnering with biotech startups or large pharmaceutical companies, Cerba Research’s contributions pave the way for transformative breakthroughs in oncology. Explore how their cutting-edge capabilities can elevate your clinical trials to new heights.